Introduction
Anabolic androgenic steroids (AAS [1]; Box 1) comprise a large class of synthetic derivatives of testosterone that are predominately taken in an illicit manner for ergogenic purposes and image enhancement [2] . An estimated 10 million Americans, some starting as early as 13 years of age, have self-administered AAS [3, 4] , a pattern that is mirrored in other countries [5] . Although most users are male, an appreciable percentage is female [4] . Thus, both age and sex are crucial parameters to consider when assessing the impact of illicit steroid use. AAS are taken in intricate and complex patterns, typified by concurrent (stacking) and intermittent (cycling) coadministration of different AAS in which doses may be increased then decreased (pyramiding) and coupled with coadministration of masking agents (Box 1) [6, 7] . The rationalization for these sophisticated regimens is the belief that activation of multiple signaling pathways will result in the synergistic augmentation of anabolic (muscle-building) effects with minimization of unwanted side-effects [7] . All illicit regimens result in supratherapeutic levels of androgens and their metabolites: by an estimated 10-100-fold in men and by >1000-fold in women and adolescents [7] [8] [9] . Thus, this rationalization aside, illicit steroid use results in highly nonphysiological levels of endogenous steroids and comparably high levels of synthetic steroids, all of which have the capacity to alter not only peripheral physiology, but also central nervous system processing and behavioral output [1, 10, 11] .
The matrix of interactions of these different steroid regimes with key variables such as age, sex, intrinsic genetic makeup, and social context promotes an array of effects that may be quite disparate from one individual to the next. With regard to behavior, data from case reports, large population surveys, and experimental studies in humans have shown that AAS use can result in a plethora of actions that range from euphoria and increased selfconfidence to impulsivity, irritability, and aggression [6, 9, 12, 13] . A growing body of literature demonstrates that behavioral outcomes of chronic AAS use are recapitulated in animal models. As such, these models provide crucial mechanistic insight into the underlying bases for AASinduced effects. Here, we review these recent studies and highlight the advances in our understanding of the neuronal mechanisms that underlie AAS-induced changes in anxiety and aggression.
The behavioral effects of AAS on anxiety As indicated above, case studies in humans demonstrate that AAS impose a wide range of changes in behaviors in individuals who use these steroids [8, 9, 12] . For example, adult men have reported transient euphoria and hypomania early in the course of AAS administration [14] , but long-term users may manifest increased anxiety and marked irritability with generalized and undirected anger [6, 12] . Men who administer the highest doses of AAS have been shown to have elevated scores on the Symptom Check List-90, a selfreport system that includes several different dimensions of anxiety, and on the Hostility and Direction of Hostility Questionnaire, which reflects both the willingness to respond to social situations with aggressive behavior and the tendency to evaluate people, including oneself, in negative terms [6] . Randomized clinical trials have been few owing to ethical constraints, and those that have been performed have been carried out using only moderate doses of a single AAS. However, men in these studies were also found to exhibit increased levels of hostility and anxiety [15, 16] . Fewer studies have examined behavioral outcomes in women or in adolescents of either sex, but in such studies the data again suggest that chronic steroid use is associated with poor self-esteem, as well as eating and mood disorders, that may reflect a fundamental disruption in the neural circuitry that regulates anxiety [17, 18] .
